The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...